
Hospitals sales from Novo Nordisk's hemophilia drug Novoseven dropped 4.3 percent in December when calculated over a four-month period and compared with a similar period leading up to November, which data from Symphony Health Solutions shows, according to Bloomberg News.
In total, Novoseven sold for USD 35.6m over 22 trade days in December, whereas the concurrent amount over 19 trade days in November was USD 33.8m.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app